Vanguard Group’s Insmed INSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$3.67B Buy
21,076,344
+1,140,524
+6% +$208M 0.05% 321
2025
Q3
$2.87B Buy
19,935,820
+2,291,328
+13% +$281M 0.04% 380
2025
Q2
$1.78B Sell
17,644,492
-623,630
-3% -$47.7M 0.03% 502
2025
Q1
$1.39B Buy
18,268,122
+49,149
+0.3% +$3.76M 0.03% 551
2024
Q4
$1.26B Buy
18,218,973
+1,075,796
+6% +$77.5M 0.02% 590
2024
Q3
$1.25B Buy
17,143,177
+1,130,167
+7% +$83.4M 0.02% 591
2024
Q2
$1.07B Buy
16,013,010
+1,503,775
+10% +$58.3M 0.02% 615
2024
Q1
$394M Buy
14,509,235
+383,714
+3% +$10.7M 0.01% 1127
2023
Q4
$438M Sell
14,125,521
-219,991
-2% -$5.7M 0.01% 1045
2023
Q3
$362M Buy
14,345,512
+1,024,956
+8% +$23.4M 0.01% 1086
2023
Q2
$281M Sell
13,320,556
-42,755
-0.3% -$811K 0.01% 1283
2023
Q1
$228M Buy
13,363,311
+322,480
+2% +$6.27M 0.01% 1386
2022
Q4
$261M Buy
13,040,831
+1,686,861
+15% +$32.6M 0.01% 1281
2022
Q3
$245M Buy
11,353,970
+106,326
+0.9% +$2.55M 0.01% 1270
2022
Q2
$222M Buy
11,247,644
+148,938
+1% +$3.12M 0.01% 1353
2022
Q1
$261M Sell
11,098,706
-21,724
-0.2% -$505K 0.01% 1376
2021
Q4
$303M Buy
11,120,430
+287,229
+3% +$8.21M 0.01% 1348
2021
Q3
$298M Buy
10,833,201
+186,495
+2% +$4.89M 0.01% 1329
2021
Q2
$303M Buy
10,646,706
+961,181
+10% +$28.5M 0.01% 1341
2021
Q1
$330M Buy
9,685,525
+322,398
+3% +$12.3M 0.01% 1245
2020
Q4
$312M Buy
9,363,127
+198,200
+2% +$7.24M 0.01% 1172
2020
Q3
$295M Sell
9,164,927
-231,822
-2% -$6.66M 0.01% 1026
2020
Q2
$259M Buy
9,396,749
+959,588
+11% +$22.7M 0.01% 1106
2020
Q1
$135M Buy
8,437,161
+261,085
+3% +$6.19M 0.01% 1353
2019
Q4
$195M Buy
8,176,076
+2,467
+0% +$50.2K 0.01% 1403
2019
Q3
$144M Buy
8,173,609
+193,672
+2% +$3.74M 0.01% 1534
2019
Q2
$204M Buy
7,979,937
+896,047
+13% +$25M 0.01% 1345
2019
Q1
$206M Buy
7,083,890
+134,506
+2% +$3.49M 0.01% 1322
2018
Q4
$91.2M Buy
6,949,384
+146,678
+2% +$2.34M ﹤0.01% 1723
2018
Q3
$138M Buy
6,802,706
+154,130
+2% +$3.48M 0.01% 1631
2018
Q2
$157M Buy
6,648,576
+220,287
+3% +$5.67M 0.01% 1513
2018
Q1
$145M Buy
6,428,289
+122,794
+2% +$3.23M 0.01% 1502
2017
Q4
$197M Buy
6,305,495
+1,638,833
+35% +$48.4M 0.01% 1313
2017
Q3
$146M Buy
4,666,662
+838,781
+22% +$16M 0.01% 1482
2017
Q2
$65.7M Buy
3,827,881
+46,398
+1% +$792K ﹤0.01% 1884
2017
Q1
$66.2M Buy
3,781,483
+173,532
+5% +$2.68M ﹤0.01% 1867
2016
Q4
$47.7M Buy
3,607,951
+123,394
+4% +$1.68M ﹤0.01% 2006
2016
Q3
$50.6M Buy
3,484,557
+72,824
+2% +$912K ﹤0.01% 1927
2016
Q2
$33.6M Buy
3,411,733
+157,786
+5% +$1.84M ﹤0.01% 2079
2016
Q1
$41.2M Buy
3,253,947
+48,583
+2% +$639K ﹤0.01% 1956
2015
Q4
$58.2M Buy
3,205,364
+254,657
+9% +$4.49M ﹤0.01% 1806
2015
Q3
$54.8M Buy
2,950,707
+1,010,487
+52% +$25.2M ﹤0.01% 1812
2015
Q2
$47.4M Buy
1,940,220
+374,487
+24% +$8.5M ﹤0.01% 1972
2015
Q1
$32.6M Buy
1,565,733
+238,500
+18% +$4.2M ﹤0.01% 2124
2014
Q4
$20.5M Buy
1,327,233
+141,491
+12% +$2.01M ﹤0.01% 2227
2014
Q3
$15.5M Buy
1,185,742
+192,697
+19% +$2.91M ﹤0.01% 2295
2014
Q2
$19.8M Buy
993,045
+53,391
+6% +$791K ﹤0.01% 2222
2014
Q1
$17.9M Buy
939,654
+85,049
+10% +$1.62M ﹤0.01% 2235
2013
Q4
$14.5M Buy
854,605
+70,167
+9% +$1.07M ﹤0.01% 2299
2013
Q3
$12.2M Buy
784,438
+121,228
+18% +$1.54M ﹤0.01% 2302
2013
Q2
$7.93M Buy
+663,210
New +$6.78M ﹤0.01% 2441

Other funds holding INSM

Vanguard Group's INSM Position: Q4 2025 in Review

Vanguard Group increased its Insmed (INSM) stake by 5.7% in Q4 2025, buying an estimated $208M and bringing the position to 21,076,344 shares worth $3.67B. The position accounts for 0.05% of the portfolio, ranked #321.

Vanguard Group first reported a position in INSM in Q2 2013 and has held it in 51 quarters since. 676 funds tracked by Wall St. Rank hold INSM as of Q4 2025.

  • Vanguard Group held 21,076,344 shares of Insmed worth $3.67B as of Q4 2025.
  • Vanguard Group bought 1,140,524 Insmed shares in Q4 2025, an estimated $208M.
  • Insmed made up 0.05% of Vanguard Group's portfolio in Q4 2025, its #321 holding.
  • Vanguard Group first reported a position in Insmed in Q2 2013 and has held it in 51 quarters since.
  • 676 funds tracked by Wall St. Rank held Insmed as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.